内科

目的探讨慢性阻塞性肺病急性发作期患者细胞免疫功能的变化，观察药物治疗效果。方法将入选的50例慢性阻塞性肺病急性发作期病人分为两组，常规组（23例）用抗感染、化痰、平喘、吸氧治疗等常规方法治疗，胸腺肽组（27例）在常规治疗基础上加用胸腺肽120 mg/d，静脉滴注，疗程2周。测定治疗前后细胞免疫功能水平。结果两组患者治疗前CD3、CD4、CD8、CD4/CD8差异无统计学意义（P＞0.05）。治疗后胸腺肽组CD3、CD4、CD4/CD8较常规治疗组明显增高（P＜0.01），CD8明显降低（P＜0.01）。胸腺肽组临床疗效优于常规治疗组（P＜0.05）。结论慢性阻塞性肺病急性发作期患者细胞免疫功能明显降低，胸腺肽能明显改善此类患者的细胞免疫功能及临床治疗效果。

ObjectiveTo explore the changes of cellular immune function in patients with acute episode of chronic obstructive pulmonary disease,and observe the effects of medication.Methods50 patients with chronic obstructive pulmonary disease in acute exacerbation were divided into two groups(Conventional group and thymosin group).Conventional therapy,such as anti-infection,phlegm reduction,relieving asthma,oxygen were used in conventional group(23 cases);thymosin group were added thymosin 120mg/d,for 2 weeks,on the basic therapy as the conventional group;then detected the cellular immune function level before and after treatment.ResultsBefore treatment,there were no significant differences between two groups in CD3、CD4、CD8、CD4/CD8(P＞0.05).Compared with the conventional group,CD3、CD4、CD4/CD8 were significantly higher in thymosin group after treatment(P＜0.01),but CD8 decreased obviously in thymosin group(P＜0.01).The efficacy of thymosin group was better than conventional group(P＜0.05).ConclusionThe cellular immune function of patients with acute episode of chronic obstructive pulmonary disease decreased significantly.Thymosin can significantly improve the cellular immune function of such patients and clinical therapeutic effect.

ref